Dataset Information


RNA-Seq analysis of prostate cancer cell line LNCaP treated with vehicle, androgen, androgen and IMTPPE, androgen and JJ-(+)-450, androgen and JJ-(-)450, androgen and enzalutamide

ABSTRACT: RNA-Seq analysis of prostate cancer cell line LNCaP treated with vehicle (C), androgen (R), androgen and IMTPPE (R + IMTPPE), androgen and JJ-(+)-450 (androgen + (-)450), androgen and JJ-(-)450 (androgen + (-)450), androgen and enzalutamide (androgen +Enz). To evaluate if our compounds can inhibit AR function specifically and completely, LNCaP mRNA profiles of cells treated with IMTPPE, (+)-JJ-450 and (-)-JJ-450, comparing to enzalutamide. RNA isolation was performed using RNeasy Mini kit (Qiagen), RNA Sequencing was carried out by Genomics Research Core of University of Pittsburgh using Illumina NextSeq 500 system. The sequence reads that passed FASTQC were analyzed at the transcript level. Each sample was mapped to the Human Ensembl reference genome GRCh38. We definied different expression genes with a fold change ≥2.0 and FDR <0.05. Both (-)-JJ-450 and enzalutamide are very specific to AR, with 56 and 186 DE genes comparing to control samples respectively. IMTPPE and (+)-JJ-450 can inhibit most of the androgen responsive genes, but also some other genes were affected. (-)-JJ-450 is a novel compound inhibts AR function specifically and completely, and it is a potential lead compound for the treatment of CRPC, including those resistant to enzalutamide.

ORGANISM(S): Homo sapiens

PROVIDER: GSE115395 | GEO | 2019/06/06


Similar Datasets

| PRJNA474819 | ENA
2018-08-01 | GSE88752 | GEO
2018-02-21 | GSE110903 | GEO
2015-10-01 | GSE62474 | GEO
2016-06-10 | E-GEOD-69896 | biostudies-arrayexpress
2021-10-05 | GSE185223 | GEO
2019-12-31 | E-MTAB-7294 | biostudies-arrayexpress
2021-09-10 | PXD024030 | JPOST Repository
2013-04-01 | E-GEOD-44905 | biostudies-arrayexpress
2016-06-10 | GSE69896 | GEO